EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF CHRONIC CARRIAGE OF SALMONELLA

被引：4

作者：

CORRADO, ML

DUPONT, HL

COOPERSTOCK, M

FEKETY, R

MURRAY, DM

机构：

[1] UNIV TEXAS,SCH MED,HLTH SCI CTR HOUSTON,CTR INFECT DIS,6431 FANNIN,1 728 JFB,HOUSTON,TX 77030

[2] UNIV TEXAS,SCH PUBL HLTH,HOUSTON,TX 77025

[3] ROBERT WOOD JOHNSON PHARMACEUT INST,DIV ANTIINFECT,RARITAN,NJ

[4] UNIV MISSOURI,MED CTR,SCH MED,DEPT PEDIAT,COLUMBIA,MO 65201

[5] PROCTER & GAMBLE CO,GEN OFF HLTH CARE,CINCINNATI,OH 45239

[6] UNIV MICHIGAN,MED CTR,DIV INFECT DIS,ANN ARBOR,MI 48109

来源：

CLINICAL INFECTIOUS DISEASES | 1992年 / 15卷

关键词：

D O I：

10.1093/clind/15.Supplement_1.S259

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The chronic carriage of salmonellae is defined as the shedding of a Salmonella species for greater-than-or-equal-to 1 year, as documented by an initial positive culture of a stool sample obtained at least 1 month after resolution of the acute illness and repeated positive cultures for at least 1 year. Clinical trials of investigational anti-infective drugs for the treatment of the salmonella carrier state may be conducted with a placebo control or an active concurrent control. A crossover design also may be employed for establishing efficacy. Patients should generally receive therapy for at least 6 weeks. Outcome will be assessed only by microbiological criteria. Determination of the interval required for the suppression of salmonellae and follow-up for 6 months after completion of therapy are recommended.

引用

页码：S259 / S262

页数：4